Last updated: July 21, 2026
Remifentanil hydrochloride is a short-acting, IV opioid used for anesthesia and procedural sedation, with core demand tied to operating-room volume and anesthesia practice patterns rather than long-course chronic regimens. In the US, patent and market-structure risk is dominated by long-standing access via authorized generics and multiple branded labels; the near-term investment case is primarily about (1) supply continuity and (2) formula/manufacturing cost and quality execution, not about new regulatory exclusivity. Upside generally comes from share gains, contract pricing, and stable hospital formularies; downside comes from margin compression, sterile-manufacturing execution risk, and supply disruptions that can trigger tender reallocations.
Is remifentanil hydrochloride a good investment: demand drivers and price/margin fundamentals?
Bottom line: Investment fundamentals skew toward “defensive hospital supply chain” dynamics. The drug is used intraoperatively and in procedural settings, typically with high facility dependence on predictable availability and rapid onset/offset pharmacology. The market behaves like a specialty injectable with procurement-led pricing, where value is captured by scale, reliability, and tender execution rather than by premium differentiation.
Demand drivers that matter commercially
- Anesthesia and OR utilization: Remifentanil is standard for general anesthesia workflows and adjunct analgesia, so demand is linked to surgical volume (elective and inpatient mix).
- Clinical protocol standardization: Hospitals standardize intraoperative analgesia kits and order sets, increasing stickiness once a product is preferred.
- Safety-driven switching limits: Clinical switching can occur, but remifentanil is often selected for titratability and rapid recovery. Replacement typically requires operational training and pharmacy/anesthesia alignment, which can slow switching cycles.
Pricing and margin mechanics
- Hospital procurement power: Formularies and group purchasing organizations pressure ASPs and drive rebidding cycles.
- Competition from multiple generics/authorized generics: In practice, the drug’s market tends to have compressed margins once supply is widely available.
- Sterile injectable economics: Cost of goods is driven by sterile manufacturing, batch yields, packaging, and regulatory quality systems. Margin resilience depends on plant reliability and utilization.
How big is the US remifentanil hydrochloride market and what are the revenue exposure risks?
Bottom line: Revenue exposure is typically concentrated in US hospital contracting and distribution channel performance. The key investment risk is not sudden therapeutic obsolescence, but contract repricing and manufacturing/supply continuity.
Revenue exposure by channel and use case
- Acute care hospitals: Main channel for anesthesia.
- Ambulatory surgery centers (ASCs): Exposure depends on procedural anesthesia protocols; uptake is less consistent than in inpatient ORs.
- Anesthesia service lines: Pharmacy and anesthesia departments influence formulary decisions through protocol governance.
Investment risks that hit P&L
- Tender repricing and price deflation: Authorized-generic presence and multiple ANDA competitors typically force periodic price concessions.
- Shortages and reallocations: Supply disruptions can create short-lived pricing power but risk longer-term exclusion from formularies after repeated incidents.
- Regulatory/manufacturing holds: Sterile injectable process deviations can produce revenue gaps.
What patents protect remifentanil hydrochloride in the US?
Bottom line: Remifentanil hydrochloride is a mature active ingredient with legacy IP. The investment case should treat the product as post-original-intellectual-property in practice unless a specific, still-in-force US patent family covers a particular dosage form, concentration, or method of use.
How to evaluate “what patents protect” in the remifentanil context
For an investment screen, protection is usually limited to one of these categories:
- Formulation or manufacturing process patents (sterile manufacturing, specific compositions, stabilizers, container closures).
- Method-of-use patents tied to dosing regimens or procedural indications.
- Combination claims (less common for remifentanil as a single-agent perioperative analgesic, but combinations can exist).
- Device or administration system claims (rare compared with formulation/process).
Actionable investment lens: The patent estate for the active ingredient itself often does not block generics. Market access is usually determined by whether any US patent is still listed in the Orange Book for specific product strengths/packaging and whether those patents are enforced through litigation.
What is the Orange Book status of remifentanil hydrochloride (Ultiva and generic equivalents)?
Bottom line: In the US, remifentanil hydrochloride’s branded access is typically maintained by legacy product listings, but generic entry is generally enabled by the maturity of the IP landscape. Orange Book status is the gating item for any new generic launch timetable.
What you should map on an investment screen
- Listed drug products by strength and dosage form (e.g., vial sizes, concentrations).
- Patent numbers and patent expiration dates for each strength.
- Exclusivity listings (5-year new chemical entity, 6-year exclusivity, pediatric exclusivity, additional exclusivity) if any exist for the reference product or specific NDA.
- Hatch-Waxman event history: Paragraph IV filings and litigation triggers.
When does remifentanil hydrochloride lose exclusivity in the US?
Bottom line: For remifentanil hydrochloride, practical market exclusivity generally ended years earlier; remaining exclusivity risk is usually tied to specific listed formulation or method-of-use patents rather than base regulatory exclusivity.
Typical exclusivity concepts that drive launch timing
- Patent expiration vs. exclusivity expiration: A generic can be blocked by a listed patent even after base exclusivity ends.
- Orange Book listed patents by strength: A generic may launch only on certain strengths if some are still patented.
- Settlement timing: Even if a patent expires, a settlement agreement can delay a launch.
How strong is the patent estate for remifentanil hydrochloride and what matters most for investors?
Bottom line: Remifentanil hydrochloride’s value is not typically protected by broad, still-in-force active-ingredient patents. The investment focus should be on whether any narrow, product-specific US patents remain enforceable and whether litigation risk is active or has been de-risked.
Patent strength indicators investors use
- Claim scope: Narrow manufacturing/process claims are easier to design around than method-of-use claims tied to standard anesthesia protocols.
- Remaining term and enforcement history: If patents are old and unasserted, market behavior may already reflect design-around success.
- Multiple-suit landscape: If courts have already constrained claim scope, future challenges become easier.
What generic entry risks exist for remifentanil hydrochloride (ANDA Paragraph IV and authorized generics)?
Bottom line: The main generic entry risk is less about whether entry is possible and more about timing, supply ramp capability, and settlement/litigation constraints that can delay specific strengths.
What to evaluate for ANDA risk
- Paragraph IV filing history for each strength: indicates active patent challenges.
- Notice of Paragraph IV litigation and whether an injunction or stipulated stay occurred.
- Settlement agreements: Common in mature markets; delays can shift launch dates and competitor strategy.
What patent litigation affects remifentanil hydrochloride and how does it change launch scenarios?
Bottom line: Mature injectable markets typically have a litigation footprint that can create short-term launch delays, but for remifentanil the most relevant investment question is whether any specific litigation remains active for relevant strengths.
Litigation-to-launch translation investors need
- Stays and injunctions: Can defer FDA approval conversion dates.
- Dismissals and claim construction outcomes: Can unblock launches quickly.
- Settlement “launch design”: Agreements often specify launch timing and sometimes product scope limits.
Are there any biosimilar risks for remifentanil hydrochloride?
Bottom line: No biosimilar regime applies. Remifentanil hydrochloride is a small-molecule generic pathway in the US (ANDA), not biologics/Biologics License Application (BLA).
Which formulations are protected by patents for remifentanil hydrochloride (strengths, vials, and excipients)?
Bottom line: For a sterile injectable opioid like remifentanil, the most plausible patent protection targets are excipient systems, concentration-specific stability, and container/closure compatibility.
Formulation categories to map
- Concentration-specific compositions: Different strengths may have different stabilizer requirements and can be different patent scopes.
- Stability and shelf-life claims: Often tied to degradation kinetics and packaging compatibility.
- Container closure system claims: Leachables/extractables or compatibility claims can matter in ANDA design-around.
How do remifentanil hydrochloride and alternative anesthesia opioids compare for competitiveness and substitution risk?
Bottom line: Competitive substitutes are typically other short-acting opioids used intraoperatively (e.g., fentanyl formulations, sufentanil, alfentanil) and anesthetic protocol choices that use opioid-sparing strategies. Substitution risk influences demand elasticity and pricing power.
Substitution factors that change procurement outcomes
- Titration and recovery profile: Remifentanil’s rapid offset is a clinical differentiator.
- Protocol inertia: Standardized anesthesia pathways slow substitution even when pricing shifts.
- Clinical preference and training: Pharmacy and anesthesia buy-in drives uptake.
What manufacturing/IP barriers affect generic competition for remifentanil hydrochloride?
Bottom line: The key barriers are sterile manufacturing capability, validation of process parameters, and robust quality systems that minimize batch failures. For investors, this typically dominates over IP barriers once patents expire or are designed around.
Practical barriers
- Sterile filtration/sterilization validation: Sterile injectable compliance.
- Stability during transport and handling: Can impact batch release and supply.
- Container compatibility: Adsorption or leachate risk.
Commercial strategy: how can an investor underwrite growth or downside in remifentanil hydrochloride?
Bottom line: Underwrite the story through execution. The drug market is not a “pipeline” opportunity; it is an “asset management and commercialization” opportunity.
Growth levers
- Share capture in hospital tenders: Win contracts by consistent availability and competitive pricing.
- Portfolio bundling: Offer anesthesia kits or multi-product procurement strategies (where permitted).
- Supply reliability: Fast fulfillment reduces wastage risk at facilities.
Downside levers
- Margin compression: Increased competition and authorized generic presence drive ASP declines.
- Supply incidents: Quality deviations can cause temporary loss of distribution and formulary exclusion.
- Regulatory compliance costs: Increasing sterile manufacturing scrutiny can raise cost of goods.
Key diligence checklist for investors (IP, Orange Book, and regulatory)
- Per strength/label Orange Book mapping: Identify any still-in-force listed patents.
- Litigation status by patent family: Check whether any remifentanil hydrochloride patent litigation is ongoing that could block or delay approval for specific strengths.
- ANDAs and launch history: Validate whether the market is already saturated and whether new entries are expected.
- Manufacturing footprint: Evaluate production plants, batch release history, and inspection outcomes.
- Contract structure: Understand rebid cadence and price reset mechanics in hospital accounts.
Key Takeaways
- Remifentanil hydrochloride is a mature, procurement-driven sterile injectable with fundamentals tied to surgical volume and OR anesthesia protocols, not to long-duration therapeutic use.
- In the US, the investment case is mainly about supply continuity, sterile manufacturing execution, and contract/repricing dynamics; remaining IP risk usually depends on product-specific Orange Book-listed patents rather than broad active-ingredient exclusivity.
- Generic competition is structurally likely once any listed patents expire or are resolved; biosimilar risk does not apply.
- The highest-impact investor diligence items are Orange Book patent-by-strength mapping, litigation and settlement history, and manufacturing reliability.
FAQs
- What drives hospital formulary selection for remifentanil hydrochloride in the US?
- How do ANDA Paragraph IV challenges typically affect remifentanil hydrochloride strength-by-strength launch timing?
- What sterile manufacturing risks most commonly disrupt supply of remifentanil hydrochloride injections?
- How do price concessions in hospital tender cycles change ASPs for sterile anesthetic opioids like remifentanil?
- What are the most likely substitution opioids in perioperative analgesia, and how does that impact remifentanil demand?
References
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” US FDA.
- FDA. “Hatch-Waxman Information.” US Food and Drug Administration.
- FDA. “Generic Drugs: Questions and Answers.” US Food and Drug Administration.
